Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy (2020) Vogel MME, Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Kirste S, Becker J, Burger IA, et al. Journal article Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study (2020) Schmidt-Hegemann NS, Kroeze SGC, Henkenberens C, Vogel MME, Kirste S, Becker J, Burger IA, et al. Journal article Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome (2020) Kessel KA, Weber W, Yakushev I, Fischer H, Voglhuber T, Diehl C, Straube C, et al. Journal article Correction to: Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA (European Journal of Nuclear Medicine and Molecular Imaging, (2019), 10.1007/s00259-019-04649-1) (2020) Schmidkonz C, Krumbholz M, Atzinger A, Cordes M, Götz T, Prante O, Ritt P, et al. Journal article, Erratum Evaluation of a Highly-Automated Dosimetry Tool-Chain for Lu-177-Therapies (2019) Ritt P, Cachovan M, Vija AH, Kuwert T Conference contribution Prevention of activated brown adipose tissue in F-18-FDG-PET-imaging in children and adolescents - Which measures are effective? (2019) Poetzsch C, Naumann S, Kurch L, Georgi TW, Weckesser M, Klutmann S, Schmidt D, et al. Conference contribution LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study) (2019) Ferone D, Pavel ME, Kunz P, De Herder W, Santoro P, Wegener A, Broberg P, et al. Conference contribution Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA (2019) Schmidkonz C, Krumbholz M, Atzinger A, Cordes M, Goetz TI, Prante O, Ritt P, et al. Journal article Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE (2019) Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, Pavel ME, Prasad V Journal article Two decades of SPECT/CT – the coming of age of a technology: An updated review of literature evidence (2019) Israel O, Pellet O, Biassoni L, De Palma D, Estrada-Lobato E, Gnanasegaran G, Kuwert T, et al. Journal article, Review article